Expanded Pharma Tariffs Target Smaller Drugmakers Over R&D Fears
October 13, 2026
Important Health - What Actually Matters
Health Policy
Talus Bio Skips Protein Folding for 5,000-Fold Drug Speed
October 14, 2026
Drug discovery speed improves 5,000-fold as Talus Bio skips protein folding to target previously undruggable proteins in their innovative screening...
READ THE ARTICLE 
FDA finalizes guidance on written responses and meeting types
October 12, 2026
AbbVie Reports High Cure Rate for Acute Hepatitis C
October 11, 2026
AI agents help manage data surge in trials
October 10, 2026
RISK FACTORS
Cancer vaccine uses COVID immune memory
Celloram develops cancer vaccine using COVID immune memory to activate T cells against tumors in mice.
Apixaban Cuts Stroke Risk in Kidney Patients
Apixaban may cut stroke risk in kidney patients with atrial fibrillation and chronic kidney disease.
Glenmark Pharmaceuticals has introduced Telma AM Biso , a fixed-dose combination tablet containing telmisartan, amlodipine, and bisoprolol for...
Tenecteplase stroke treatment may significantly reduce door-to-needle times compared to alteplase, improving outcomes for acute ischemic stroke patients.
UNC researchers test doulas and alerts to improve Black maternal health outcomes in a major $10 million study...
Three healthcare programs use data to solve real problems in maternal, infant health and veteran care—proven innovations with...
All Post
Talus Bio Skips Protein Folding for 5,000-Fold Drug Speed
Drug discovery speed improves 5,000-fold as Talus Bio skips protein folding to target previously undruggable proteins in their innovative screening...
Expanded Pharma Tariffs Target Smaller Drugmakers Over R&D Fears
Expanded pharma tariffs now target mid-sized and smaller drugmakers, raising R&D costs and industry concerns over innovation and pricing strategies.
FDA finalizes guidance on written responses and meeting types
The FDA has finalized its guidance on written responses and meeting types, revising circumstances for INTERACT meetings under the Prescription...
AbbVie Reports High Cure Rate for Acute Hepatitis C
AbbVie's Maviret achieved a 96% cure rate in a Phase 3 trial for acute hepatitis C, leading to U.S. approval...
AI agents help manage data surge in trials
Phase-3 clinical trials are generating unprecedented data volumes, a trend that fuels the vision of an autonomous clinical trial while...
Peptides face metabolic stability challenges
Peptides face metabolic stability challenges in treating diseases like obesity and cardiovascular disorders with peptide therapeutics.
Medable AI Agent Promises $21M Value in Clinical Trials
Medable's AI agent promises about $21M value in clinical trials, offering an 82x ROI for phase 3 studies.
Cancer vaccine uses COVID immune memory
Celloram develops cancer vaccine using COVID immune memory to activate T cells against tumors in mice.
Digital pathology enables virtual controls reduces animal testing
During the COVID-19 pandemic, the need for remote work pushed digital pathology from a niche tool to a core component...
New Drug Survodutide Shows Promise for Obesity, Diabetes
Survodutide shows promise as a treatment for obesity and diabetes, with significant weight loss and improved glycaemic control in trials.